Japan headquartered Toray has announced that a small size of TORAYMYXIN^TM (PMX-05R) had obtained EC certificate and is launched in the EU market on this month.

TORAYMYXIN^TM is indicated for use in the treatment of patients with sepsis or septic shock caused by gram-negative bacteria. The small size had been developed for patients with low body weight, who may not have enough blood volume to perform blood purification therapy with a regular size of TORAYMYXIN^TM (PMX-20R). In Japan, we already had been launched PMX-05R. For overseas, Toray has decided to launch PMX-05R in response to strong requests from clinical sites in EU.

 Sepsis is a global health crisis. According to Global Sepsis Alliance, it affects 27 to 30 million people every year and 7 to 9 million die – one death every 3.5 seconds. Toray expects the launch of PMX-05R in EU market can be one of the opportunities and choices for the treatment of more sepsis patients. Toray strives for sustained growing along with social contribution by realizing our corporate philosophy, “Contributing to society through the creation of new value with innovative ideas, technologies and products”, by developing high-value added materials for medical applications using advanced technology.